CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment

Core Viewpoint - CROSSJECT is enhancing its manufacturing capabilities with the implementation of the ZENEO® Nest module, aimed at scaling up production in anticipation of the deployment of its product pipeline, particularly the ZEPIZURE® emergency injectable for epilepsy management [2][3]. Group 1: Manufacturing Innovations - The ZENEO® Nest is designed for automated, high-volume aseptic filling of proprietary glass drug containers, allowing for faster and more efficient production [3][4]. - This new module is compatible with various filling setups in the CDMO industry, enabling CROSSJECT to establish ready-to-use filling units with CDMO partners globally as demand increases [3][5]. Group 2: Implementation Timeline - The first ZENEO® Nest has been successfully tested with EUROFINS, and full implementation is expected by December 2025, followed by qualification and validation steps by Q1 2026 [4][9]. Group 3: Financial Aspects - The deployment of the ZENEO® Nest is partially financed through an equipment loan from LCL, reflecting CROSSJECT's strategy to diversify its financing sources [6][9]. Group 4: Company Overview - CROSSJECT is a specialty pharmaceuticals company focused on developing emergency medications, with its ZENEO® platform facilitating easy delivery of drugs via intramuscular injection [7][8]. - The company is in advanced regulatory development for ZEPIZURE®, supported by a $60 million contract with BARDA [7].